Genesis Therapeutics unifies AI and biotech to accelerate the discovery of new medicines.
Genesis Molecular AI has raised $40.0M in total funding. The most recent round was Corporate Round. The last funding was announced in May 2026.
Genesis Molecular AI's investors include Andreessen Horowitz, Menlo Ventures, BlackRock, Radical Ventures, Felicis.
Genesis Molecular AI is headquartered in South San Francisco, United States.
Genesis Therapeutics unifies AI and biotech to accelerate the discovery of new medicines.
Genesis Molecular AI is at the Corporate Round stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Genesis Molecular AI — Funding & Investors." VCBacked, May 20, 2026, https://www.vcbacked.co/company/genesis-molecular-ai. Accessed July 18, 2026.
VCBacked. (2026). Genesis Molecular AI — Funding & Investors. Retrieved July 18, 2026, from https://www.vcbacked.co/company/genesis-molecular-ai
{{cite web |title=Genesis Molecular AI — Funding & Investors |url=https://www.vcbacked.co/company/genesis-molecular-ai |website=VCBacked |access-date=July 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated